SLC5A1 and type 2 diabetes mellitus: To date, several large cardiovascular outcome trials in high-risk T2DM patients have been conducted with selective SGLT2 inhibitors [2,3,4,5,6] and one with the dual SGLT1/2 inhibitor sotagliflozin [7].